Biotech Investment Paradigm
News
DUSA Pharmaceuticals Shares Tumble After Earnings Release: Low Growth Ahead?
DUSA Pharmaceuticals, Inc. (DUSA) – based in Wilmington, MA is a dermatology company engaged in the development and commercialization of Levulan photodynamic therapy (PDT). Utilizing their proprietary Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses (AKs) of the face or scalp, the company [...]
Inhibitex Announces Positive Topline Data in HCV Program
Last week, Inhibitex (NASDAQ: INHX) updated guidance on its program in HCV with positive top-line data from the first cohort of a trial of INX-189 in treatment-naïve patients infected with genotype 1 HCV. Patients in this arm received 200 mg of Inhibitex’s nucleotide polymerase inhibitor INX-189 once daily and saw a median reduction in viral [...]
Seattle Genetics Updates Investors on Adcetris Launch and Label Expansion
Seattle Genetics (NASDAQ: SGEN) announced third quarter results on Thursday, updating investors on the Adcetris launch and plans for confirmatory trials and label expansion studies. On August 19th, Adcetris received accelerated approval for relapsed or refractory Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), marking a major milestone for Seattle Genetics with its first product [...]
LPath Investors Have iSONEP Trial Results in Sight
Upcoming events: PEDigree phase Ib/2a preliminary data late Q1 2012 or early Q2 2012 LPath, Inc. (LPTN.OB) – based in San Diego, CA engages in the development and commercialization of lipidomic-based therapeutics. Utilizing their proprietary ImmuneY2™ discovery engine, the company aims to leverage its technology platform to provide monoclonal antibodies targeting bioactive lipids in a [...]
© 2012 Biotech Investment Paradigm. All Rights Reserved.
Powered by WordPress. Designed by 